InvestorsHub Logo
Followers 827
Posts 119469
Boards Moderated 15
Alias Born 09/05/2002

Re: None

Thursday, 11/30/2017 7:21:28 PM

Thursday, November 30, 2017 7:21:28 PM

Post# of 1162
Opdivo shows OS benefit in Chinese NSCLC second-line patients:

https://news.bms.com/press-release/corporatefinancial-news/checkmate-078-pivotal-multinational-phase-3-opdivo-nivolumab-l

The comparator arm was docetaxel.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BMY News